Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Санкт-Петербургский государственный университет
Список исп. литературыСкрыть список 1. Авруцкий Г.Я., Гурович И.Я., Громова В.В. Фармакотерапия психических заболеваний. М.: Медицина, 1974. 2. Авруцкий Г.Я., Недува A.A. Лечение психически больных. М.: Медицина, 1988. 3. Вовин Р.Я. Шизофренический дефект (диагностика, патогенез, лечение). СПб.: Психоневрологический институт им. В.П.Бехтерева, 1991. 4. Костерин Д.Н. Оптимизация стационарной терапии больных шизофренией с применением атипичных антипсихотиков. Автореф. дис. … д-ра мед. наук, 2005. 5. Мосолов С.Н. Основы психофармакотерапии. М.: Восток, 1996. 6. Нуллер Ю..Л. Практические аспекты психофармакотерапии: трудности и ошибки. Психиатр. и психофармакотер. 2002; 4 (1): 16–8. 7. Пантелеева Г.П. Терапия основных форм шизофрении. В кн.: Руководство по психиатрии. Под ред. A.C.Тиганова. T. 1. М.: Медицина, 1999; с. 528–37. 8. Сиволап Ю.П., Савченков В.А. К проблеме рационального применения нейролептиков в наркологической практике. Наркология. 2007; 1: 32–7. 9. Смулевич А.Б., Пантелеева Г.П. Некоторые актуальные проблемы клинической психофармакологии. Журн. невропатол. и психиатр. 1983; 9: 1345–51. 10. Adityanjee A, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiat 2002; 63 (Suppl. 13): 32–8. 11. Ahearn EP, Juergens T, Cordes T et al. A review of atypical antipsychotic medications for post-traumatic stress disorder. Int Clin Psychopharmacol 2011; 26 (4): 193–200. 12. Akerele E, Levin FR. Comparison of olanzapine to risperidone in, comparison of olanzapine to risperidone in abusing with schizophrenia. Am J Addict 2007; 16: 260–8. 13. Alessi-Severini S, Biscontri RG, Collins DM et al. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996–2006. Psychiat Serv 2008; 59 (5): 547–53. 14. Altamura AC, Serati M, Buoli M et al. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 2011; 26 (4): 201–5. 15. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiat 2001; 158: 1–52. 16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd ed. Washington: Association 1987. 17. Anton R, Breder C, Han J et al. Aripiprazole in the treatment of alcohol dependence: results from a multisite study. Neuropsychopharmacol 2006; 31 (Suppl. 1): 200. 18. Anton RF, Kranzler H, Breder C et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008; 28 (1): 5–12. 19. Aras S, Varol Tas F, Unlu G. Medication prescribing practices in a child and adolescent psychiatry outpatient clinic. Child Care Health Dev 2007; 33 (4): 482–90. 20. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiat 2007; 46 (5): 558–65. 21. AstraZeneca. A multi-center, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended-release (Seroquel XR™) as mono-therapy in the treatment of elderly patients with major depressive Disorder (SAPPHIRE STUDY). http://www.astrazenecaclinicaltrials.com/ _mshost800325/content/clinicaltrials/resources/pdf/8579646 ClinicalTrials.gov ID NCT00388973. Study code: D1448C00014 22. AstraZeneca. A multicenter, double-blind, randomized-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR™) as monotherapy in the maintenance treatment of patients with major depressive disorder following an open-label stabilization period (AMETHYST STUDY) 2008. 23. AstraZeneca. A multi-centre, double-blind, randomised, parallel group, placebo-controlled and active controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR TM) as mono-therapy in the treatment of adult patients with major depressive disorder (AMBER STUDY). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinicaltrials/resources/pdf/8579603 ClinicalTrials.gov ID NCT00351169. Study code: D1448COOO04 24. Atik L, Erdogan A, Karaahmet E et al. Antipsychotic prescriptions in a university hospital outpatient population in Turkey: a retrospective database analysis, 2005–2006. Prog Neuropsychopharmacol Biol Psychiat 2008; 32 (4): 968–74. 25. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiat 1998; 155: 548–51. 26. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD003476. 27. Bandelow B, Chouinard G, Bobes J et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2009; 13 (3): 305–20. 28. Barnett SD, Kramer ML, Casat CD et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16 (4): 365–8. 29. Bartzokis G, Lu PH, Turner J et al. Adjunctive risperidone in the treatment of chronic combat-related post-traumatic stress disorder. Biol Psychiat 2004; 57 (5): 474–9. 30. Bauer M, Pretorius HW, Constant EL et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiat 2009; 70 (4): 540–9. 31. Belli H, Ural C, Akbudak M. Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment. J Clin Med Res 2012; 4 (5): 301–8. 32. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiat 2006; 67 (7): 1042–6.